An in situ study of beta-glucosidase activity in normal and Gaucher fibroblasts with fluorogenic probes.
Beta-glucosidase activity was evaluated in situ by means of fluorogenic probes in normal human fibroblasts and fibroblasts from homozygous carriers of the Gaucher trait. Probe internalization, targeting to lysosomes and post-cleavage probe retention were the primary concerns. Internalization and targeting were attempted by in situ photosensitized labilization of lysosomal membranes, lysosomotropic detergents and the use of low density lipid (LDL) or the receptor ligand apolipoprotein E (ApoE). Post-cleavage increase of fluorescence with fluoresceinyl (bis) beta-glucopyranoside was appreciably above the rather large pre-cleavage emission. In cells incubated overnight with nonylumbelliferyl-beta-glucoside (UG9) in the presence of bovine serum albumin and in the absence of ApoE, the probe was dealt with as a cytotoxic agent, accumulating in a paranuclear cap, most likely comprising elements of the endoplasmic reticulum (ER) and Golgi apparatus. Targeting of UG9 to lysosomes occurred within 1 to 3 h of preincubation in the presence of ApoE. There was some evidence of specificity, as Gaucher fibroblasts exhibited weaker cleavage of UG9 (by 50 per cent or more) compared to normal fibroblasts, but in the Gaucher cells there was some residual beta-glucosidase activity. Cleavage of UG9 was nearly totally suppressed in Gaucher cells treated with the beta-glucosidase inhibitor, conduritol B epoxide, for 24 h to 7 days. Suppression in the control fibroblasts was evident but to a lesser degree. The in situ method of fluorogenic assay established for beta-glucosidase deficiency, is in principle applicable to enzyme deficiencies in other lysosomal storage diseases, or to evaluate enhanced enzyme activity following gene therapy.
Kohen
E
E
Department of Biology, University of Miami, Coral Gables, Florida 33124.
Kohen
C
C
Hirschberg
J G
JG
Santus
R
R
Grabowski
G
G
Mangel
W
W
Gatt
S
S
Prince
J
J
D002478:Cells, Cultured; D005347:Fibroblasts / Q000201:enzymology*; D005456:Fluorescent Dyes; D005776:Gaucher Disease / Q000201:enzymology*; D006027:Glycosides / Q000378:metabolism; D006720:Homozygote; D006801:Humans; D007294:Inositol / Q000031:analogs & derivatives / Q000494:pharmacology; D008247:Lysosomes / Q000201:enzymology; D008856:Microscopy, Fluorescence; D015335:Molecular Probes; D013050:Spectrometry, Fluorescence; D001616:beta-Galactosidase / Q000187:drug effects / Q000378:metabolism*; D001617:beta-Glucosidase / Q000037:antagonists & inhibitors
D005456:Fluorescent Dyes; D006027:Glycosides; D015335:Molecular Probes; D007294:Inositol; D001617:beta-Glucosidase; D001616:beta-Galactosidase; C011423:conduritol epoxide